July 2022: According to the most recent research conducted by Emergen Research, the global market for CAR T-cells therapy reached a size of USD 1.29 billion in 2021 and is expected to register a ...
June 2022: According to the findings of a study that was just recently published by Stanford Medicine in mice, a cancer treatment that makes use of a patient's own genetically modified immune cells i...
April 2022: According to preliminary data from a phase I/II clinical trial that was presented during the AACR Annual Meeting 2022, which was held from April 8-13, a new chimeric antigen receptor (CAR...
Nov 2021: The first clinical trial of South Korea's homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to circumvent immune checkpoint signals, has recently...
May 2022: T-cell therapy has begun a vigorous attack on digestive system malignancies, and T-cell immunotherapy has triumphed over refractory tumours like gastric cancer, liver cancer, and pancreatic ...
May 2022: FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumours in a CAR-NK clinical trial. The FDA approved an Investigational New Drug Applicatio...
May 2022: Matthew is a 27-year-old patient with Acute Lymphoblastic Leukemia who was diagnosed in 2015. Unfortunately, the standard treatment of chemotherapy and bone marrow transplantation failed. He...
Induction therapy followed by stem cell transplantation has maintained a role in the treatment of mantle cell lymphoma (MCL), according to James Gerson, MD, who added that he continues to recommend tr...
April 2022: Pembrolizumab (Keytruda, Merck) was approved by the Food and Drug Administration as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability-high...
China's National Medical Products Administration (NMPA) has approved JW Therapeutics' investigational new drug (IND) application for a key clinical trial of Carteyva (relmacabtagene autoleucel) in peo...